论文部分内容阅读
目的研究妊娠期高血压疾病患者静脉血清及胎儿脐血中内脂素(visfatin)和巨噬细胞移动抑制因子(MIF)的含量变化及意义。方法采用酶联免疫吸附法(ELISA)进行Visfatin和MIF含量的测定,分别测定90例妊娠期高血压疾病患者(其中妊娠期高血压、轻度子痫前期、重度子痫前期各30例)及30例正常对照组产妇静脉血清及胎儿脐血中Visfatin和MIF的含量。结果 Visfatin和MIF在妊娠期高血压疾病组及对照组血清及胎儿脐血中均有表达。MIF在妊娠期高血压疾病各组血清中含量与对照组血清中的比较,有显著性差异(t=7.31,9.82,10.04,P均<0.05),同时重度子痫前期组比轻度子痫前期和妊娠期高血压组含量高(t=7.23,8.95,P均<0.05);轻度子痫前期组含量高于妊娠期高血压组(t=7.68,P<0.05)。妊娠期高血压疾病各组血清中Visfatin含量均比对照组血清中含量高(t=7.83,质9.85,10.51,P均<0.05),且重度子痫前期组高于轻度子痫前期、妊娠期高血压组(t=7.68,8.73,P均<0.05);轻度子痫前期组含量高于妊娠期高血压组(t=7.69,P<0.05)。妊娠期高血压疾病患者Visfatin和MIF含量呈正相关(r=0.67,P<0.01)。Visfatin和MIF在妊娠期高血压疾病各组胎儿脐血中的含量,差异无显著意义(P>0.05)。结论 Visfatin和MIF的高表达,说明妊娠期高血压疾病患者存在炎症损伤,且Visfatin和MIF在损伤过程中起作用。
Objective To study the changes and significance of visfatin and macrophage migration inhibitory factor (MIF) in venous and fetal umbilical blood of patients with gestational hypertension. Methods The levels of Visfatin and MIF were measured by enzyme-linked immunosorbent assay (ELISA). The levels of Visfatin and MIF in 90 patients with gestational hypertension were detected respectively (including 30 cases of gestational hypertension, 30 cases of mild preeclampsia and 30 cases of severe preeclampsia) The content of Visfatin and MIF in maternal venous serum and fetal umbilical blood in 30 normal controls. Results Visfatin and MIF were expressed in both serum and fetal umbilical cord blood in patients with gestational hypertension and controls. There were significant differences in serum levels of MIF in gestational hypertension among all groups (t = 7.31,9.82,10.04, P <0.05), and severe preeclampsia than mild eclampsia The content of preeclampsia and gestational hypertension group was higher (t = 7.23,8.95, P <0.05). The content of mild preeclampsia group was higher than that of gestational hypertension group (t = 7.68, P <0.05). The levels of serum Visfatin in gestational hypertension were higher than those in the control group (t = 7.83, 9.85, 10.51, P <0.05 respectively), and the levels of Visfatin in severe preeclampsia group were higher than those in mild preeclampsia and pregnancy (T = 7.68, 8.73, P <0.05). The level of mild preeclampsia group was higher than that of gestational hypertension group (t = 7.69, P <0.05). There was a positive correlation between Visfatin and MIF in patients with gestational hypertension (r = 0.67, P <0.01). The levels of Visfatin and MIF in umbilical blood of fetuses with gestational hypertension were not significantly different (P> 0.05). Conclusions The high expression of Visfatin and MIF, indicating that there is inflammatory injury in patients with hypertensive disorders of pregnancy, and Visfatin and MIF play a role in the process of injury.